STAT+: Novo Nordisk ends deal with Hims due to compounding concerns with obesity drugs

Novo Nordisk is ending a deal with telehealth company Hims & Hers, saying Monday that Hims has been engaging in “illegal mass compounding” of GLP-1 obesity treatments and “deceptive marketing.”

Earlier this year Novo launched a direct-to-consumer website that sells Wegovy at a lower price to patients who are paying on their own without insurance. It also struck deals with telehealth companies, including Hims, that allowed patients to order this lower-priced Wegovy directly on their sites.

Novo said it made this offering to transition patients who were using cheap compounded drugs onto its branded treatment. 

Continue to STAT+ to read the full story…